BioSpace News Archive

KARL STORZ Imaging of Goleta, California, celebrates its 30th anniversary on November 12, 2020.

ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that its software-as-a-service division is expanding its solutions portfolio into new markets to provide data interoperability and accounts receivable optimization to the healthcare industry.

TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, has been invited to present at the Jefferies Virtual London Healthcare Conference, taking place virtually from November 17-19, 2020.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the formation of a partnership with Baylor College of Medicine in Houston, Texas to act as the lead clinical site for the Company’s upcoming Phase III clinical trial.

PainReform Ltd. welcomes Dr. Ellen Baron as a member of the Company’s Board of Directors following its recent initial public offering.

Lexogen GmbH, a Vienna-based market leader in Next-Generation Sequencing (NGS) and transcriptomics announced today the launch of a pioneering ultra-high-throughput SARS-CoV-2 test that will allow for the first time a true mass screening of the whole population.

ENDRA Life Sciences Inc. will be presenting at this year’s virtual Fall Investor Summit on November 16th-18th.

Halberd Corporation disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang Chen of Arizona State University.

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience, announced today the presentation of new preclinical data on its VI

Pressure Point Inc. has submitted its Pre-Emergency Use Authorization (EUA) interactive request to the U S Food & Drug Administration (FDA) CDRH division for approval of its Pressure Right®2 Patent-Pending, Medical Therapy Device during the COVID-19 Pandemic.